Authors: Moshkowitz, M.; Konikoff, F.M.; Peled, Y.; Brill, S.; Hallak, A.; Tiomny, E.; Santo, M.; Bujanover, Y.; Gilat, T.

Source: Alimentary Pharmacology & Therapeutics, Volume 10, Number 6, 1 October 1996 , pp. 1015-1019(5)

Publisher: Wiley-Blackwell

Abstract:

Background: Triple therapy with omeprazole, clarithromycin, and tinidazole (OCT) has been found to be highly effective against Helicobacter pylori infection. However, its efficacy as a second line regimen for patients who failed metronidazole-based triple therapy has not been evaluated.

Aim: The aim of this study was to evaluate the efficacy of low-dose, short-term OCT therapy in an Israeli population, and to compare results obtained in previously treated and untreated patients.

Methods: Patients with duodenal or gastric ulcers and chronic antral gastritis with H. pylori infection as assessed by rapid urease test and/or 14C urea breath test (14C-UBT), were studied. All patients received omeprazole 20 mg b.d., clarithromycin 250 mg b.d. and tinidazole 500 mg b.d. for 7 days. Eradication was assessed by 14C-UBT 4 weeks after treatment.

Results: One hundred and fourty-four patients (M/F=81/63) were enrolled (mean age 48.1 years, range 12-78). Eradication of H. pylori was significantly different between patients who were initially treated with this regimen (90/94, 96%) and patients who had previously failed to eradicate H. pylori with standard triple therapy (27/50, 54%). Moreover, the eradication rate was significantly decreased in patients with more than one previous failure (9/22, 41%) compared to that in patients with only one failure (18/29, 62%). No other differences such as age, gastric pathology, ethnic origin, smoking habits, or pre-treatment urease activity were found to influence the eradication rate.

Conclusions: One-week low-dose triple therapy with OCT is highly effective as an initial therapy in eradicating H. pylori infection. The efficacy is significantly lower when given as a second line treatment in patients who have previously failed to eradicate H. pylori with bismuth-based standard triple therapy.

Document Type: Research article

Affiliations: 1: Department of Gastroenterology, Ichilov Hospital, Tel-Aviv Medical Centre and Sackler Faculty of Medicine, Tel-Aviv University, Israel

Publication date: 1996-10-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Pathology ,  Pharmacology ,  Surgery ,  Therapeutics & Alternative Medicine
• By this author: Moshkowitz, M. ;  Konikoff, F.M. ;  Peled, Y. ;  Brill, S. ;  Hallak, A. ;  Tiomny, E. ;  Santo, M. ;  Bujanover, Y. ;  Gilat, T.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers